Immunotherapy Biotech HCW Biologics Inc is in Phase 2 biotech developing novel immunotherapies for cancer, filed with the SEC to raise to $50 million in an initial public offering. The company is focused on developing novel immunotherapies
HCW Biogics Inc immunotherapies is to lengthen the healthspan by disrupting the link between chronic, low-grade inflammation, and age-related diseases. Its gateway evidence is oncology. The immunotherapy Biotech expects to have four active trials to evaluate its molecules for cancer indications by the end of 2021. The company’s molecule HCW9201 is currently being evaluated for the generation of memory-like NK cell products in two ongoing Phase 2 trials for relapsed/refractory acute myeloid leukemia, with preliminary data expected in the 2H21.
HCW will oversee the manufacturing and supply of these proteins to Wugen. Wugen will research, develop, and commercialize cell therapeutic products on a worldwide basis. The patented molecules generated by HCW allow for the robust activation and expansion of immune cells to significantly lower the cost of goods, enabling greater patient access to these important cellular therapies.CAR-T and NK cells have shown remarkable activity in the clinic in the treatment of cancer, but significant challenges remain about generating sufficient numbers of highly active, robust immune cells.